

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

宜明昂科生物醫藥技術（上海）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1541)

VOLUNTARY ANNOUNCEMENT APPOINTMENT OF CHIEF BUSINESS OFFICER

The board (the “**Board**”) of directors (the “**Director(s)**”) of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “**Company**,” together with its subsidiaries, the “**Group**”) is pleased to announce that Dr. Weihai He (“**Dr. He**”) was appointed as a Chief Business Officer of the Group with effect from May 5, 2025. Dr. He is based in the United States and reports directly to Dr. Tian Wenzhi, the founder, Chairman of the Board, Chief Executive Officer and Chief Scientific Officer of the Company.

Dr. He is an experienced life sciences executive with extensive expertise in business development, strategic marketing, product management, finance, and pharmaceutical R&D. Prior to joining our Group, Dr. He served on the board of supervisors of the Global Health Drug Discovery Institute (全球健康藥物研發中心), a non-profit research organization jointly founded by the Bill & Melinda Gates Foundation, the Tsinghua University Education Foundation, etc., from December 2021 to May 2025. She also served as a deputy director of business development and licensing at Bill and Melinda Gates Foundation from 2021 to May 2025, leading business development and licensing efforts on presidential priority projects aimed at developing high-impact interventions to address the leading causes of death and disability in developing countries. In 2021, Dr. He served as the senior vice president and head of global business development and commercialization at Evive Biotech in San Francisco, the United States, where she led the global business development team for out-licensing and in-licensing, and developed commercial strategies for global product launches. From 2019 to 2021, Dr. He served as a senior director and head of business development at Merck KGaA (FRA: MRK), a global science and technology company listed on the Frankfurt Stock Exchange, responsible for business development and alliance management. She worked at Genentech Inc., in San Francisco, California, from 2007 to 2019 in diverse array of functions. Prior to that, Dr. He served as a senior scientist in product research and development at Panomics, Inc. (formerly known as Genospectra Inc.), a biotechnology

company in Fremont, California, from 2003 to 2005, and served as a postdoctoral scientist of drug discovery at Tularik Inc., a biotechnology company later acquired by Amgen (Nasdaq: AMGN), from 2001 to 2003, where she led a team to identify natural ligands for drug targets.

Dr. He obtained a bachelor's degree in biology from Peking University (北京大學) in the PRC in 1995, a Ph.D. in molecular and cellular biology from the University of Arizona in the United States in 2001, and a master's degree in business administration (MBA) from the Wharton School of the University of Pennsylvania, in the United States in 2007.

By order of the Board
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
宜明昂科生物醫藥技術（上海）股份有限公司
Tian Wenzhi
Chairman and Executive Director

Shanghai, the PRC, May 6, 2025

As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi, Mr. Li Song and Ms. Guan Mei as executive Directors; (ii) Dr. Xu Cong as non-executive Director; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.